Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777244 | 1.00 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL15021133 | 1.00 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL168286 | 1.00 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL21772974 | 1.00 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| Hydrochloric Acid SCHEMBL4995917 | 0.98 | CHRM2 (0.61) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| Hydrochloric Acid SCHEMBL4020237 | 0.96 | CHRM2 (0.59) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL20967986 | 0.93 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL9023345 | 0.93 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL8120312 | 0.93 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 | |
| SCHEMBL21266577 | 0.91 | CHRM2 (0.65) | CHRM2CHRM4CHRM5CHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | claimed |
| EP-0861252-B1 | NAPHTHAMIDE DERIVATIVES OF 3 BETA-AMINO AZABICYCLO OCTANE OR NONANE AS NEUROLEPTIC AGENTS | PF MEDICAMENT (FR) | 2000-02-23 | — | — | EP | claimed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| CN-117729914-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-10556899-B2 | Method for preparing Maraviroc | SCI PHARMTECH, INC. (TW) | 2020-02-11 | — | — | US | disclosed |
| EP-0081054-A2 | Azabicyclo alkyl derivatives | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0069481-A1 | Azabicycloalkyl benzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-01-12 | — | — | EP | disclosed |
| EP-0069482-A1 | Azabicycloalkyl benzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-01-12 | — | — | EP | disclosed |
| EP-0068700-A1 | Azobicycloalkylbenzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-01-05 | — | — | EP | disclosed |
| EP-0055524-A2 | Bicyclo (3,2,1) octylbenzamides, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1982-07-07 | — | — | EP | disclosed |
| US-4336259-A | DOPAMINE ANTAGONIST, NERVOUS SYSTEM DISORDERS AND GASTROINTESTINAL DISORDERS | BEECHAM GROUP LIMITED (GB) | 1982-06-22 | — | — | US | disclosed |
| EP-0042705-A1 | Azabicycloalkane derivatives, their preparation and use | BEECHAM GROUP PLC (GB) | 1981-12-30 | — | — | EP | disclosed |
| US-4273778-A | TREATMENT OF GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, AND PSYCHOLOGICAL DISORDERS | BEECHAM GROUP, LIMITED (GB) | 1981-06-16 | — | — | US | disclosed |
| EP-0013138-A1 | Azabicycloalkyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | CHRM2 21/4885CHRM4 190/4885CHRM5 162/4885 |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | CHRM2 4797/4885CHRM4 4734/4885CHRM5 4726/4885 |
| US-10556899-B2 | Method for preparing Maraviroc | CYP3A43, NAT10, CYP3A5 | CHRM2 456/4885CHRM4 795/4885CHRM5 574/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | CHRM2 194/4885CHRM4 290/4885CHRM5 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.